Have patients born before 1991?
Identifying patients just got easier.
The CDC now recommends UNIVERSAL adult hepatitis B vaccination1-3,*
Protecting your adult patients can be as
Patients born before 1991?
Use 2 doses, 1 month, done.1,3,4
WHY DO YOU NEED TO UNIVERSALLY VACCINATE?
While the 1991 pediatric policy helped decrease rates of hepatitis B in children, adults are still vulnerable and cases are on the rise5,6
In 2019
of new cases were among adults aged 30 to 49 years5
In many states, the rate of new cases in adults has increased in the last decade5,7
To combat the growing number of hepatitis B cases, the CDC now recommends universal hepatitis B vaccination for all adults.3,5,*
Millions of adults still need hepatitis B vaccination5,8,†
born before 1991 do not have vaccine-induced immunity6
The hepatitis B vaccine could become the most widely used non-flu vaccine for adults in your pharmacy.8,†
The CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.3
Adults eligible for influenza vaccines calculated from population aged 18+ in 2022; adults eligible for shingles vaccines calculated using adults turning 50 years old in 2022, adults aged >50 who are unvaccinated based on CDC coverage rates, and immunocompromised adults aged 19-49; adults eligible for pneumonia vaccines included adults aged 65+ and at-risk adults aged 18-64 excluding smokers, patients with chronic heart disease, and patients who are immunocompromised; adults eligible for hepatitis B vaccination calculated using US census data published in 2018, CDC coverage data, and risk factor analyses. COVID vaccines were not part of this analysis.8
ROUTINE HEPATITIS B PROTECTION STARTS WITH YOU3
Follow these steps to get your patients protected:
IDENTIFY
all patients born before 19911,3
RECOMMEND
A strong recommendation helps protect more patients9
PROTECT
with HEPLISAV-B: 2 doses, 1 month, done4
How to get the conversation started with your patients:
How to get the conversation started with your patients:
Based on your date of birth, you likely did not receive the hepatitis B vaccination series as a child. The CDC now recommends that adults get caught up, and I recommend that you get started today with HEPLISAV-B. It’s just 2 doses in 1 month and you’re done.1,3,4,‡
The CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.3
PATIENTS BORN BEFORE 1991? USE 2 DOSES, 1 MONTH, DONE.1,3,4
HEPLISAV-B is the first and only 2-dose adult hepatitis B vaccine that provides series completion in just 1 month3,4,10
![HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[2,8]](/_nuxt/img/HEPLISAV-B_series_completion_pharmacists-m.b1cd4b7.png "HEPLISAV-B 2-dose 1-month vs Engerix-B graphic")
![HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[2,8]](/_nuxt/img/HEPLISAV-B_series_completion_pharmacists.fffebce.png "HEPLISAV-B 2-dose 1-month vs Engerix-B graphic")
Clinical studies have shown faster protection with HEPLISAV‑B4,12
EXPLORE DATAACCESS TO HEPLISAV-B
HEPLISAV-B is covered by most insurance plans and may be billed as a medical or prescription benefit (NDC#: 43528-0003-05)
PHARMACISTS ARE CRITICAL TO THE SUCCESS OF THE UNIVERSAL ADULT HEPATITIS B VACCINATION POLICY3,§
Take the lead: identify patients, recommend vaccination, and start protecting today with HEPLISAV-B1,3,4,9
Patients born before 1991?
Use 2 doses, 1 month, done.1,3,4
HEPLISAV-B NDC#: 43528-0003-05
Looking for more information on HEPLISAV-B?
Get ResourcesThe CDC recommends hepatitis B vaccination for all adults aged 19-59 and adults aged ≥60 with hepatitis B risk factors. Adults aged ≥60 without risk factors may receive hepatitis B vaccination.3
INDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.
Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.
Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.
The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).
Please see full Prescribing Information.
References: 1. Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13):1-19. 2. Freedman M, Kroger A, Hunter P, Ault KA. Recommended adult immunization schedule, United States, 2020. Ann Intern Med. 2020;172(5):337-347. doi:10.7326/M20-0046 3. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2023. Accessed April 4, 2023. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 4. HEPLISAV-B. Package insert. Dynavax Technologies Corporation; 2020. 5. Weng MK, Doshani M, Khan MA, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):477-483. doi:10.15585/mmwr.mm7113a1 6. He WQ, Guo GN, Li C. The impact of hepatitis B vaccination in the United States, 1999-2018. Hepatology. 2022;75(6):1566-1578. doi:10.1002/hep.32265 7. Hepatitis B Foundation. Hepatitis B facts and figures. Accessed March 8, 2022. https://www.hepb.org/what-is-hepatitis-b/what-is-hepb/facts-and-figures 8. Data on file. Dynavax Technologies Corporation; 2023. 9. Bjork A, Morelli V. Immunization strategies for healthcare practices and providers. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:29-42. 10. Haber P, Schillie S. Hepatitis B. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Public Health Foundation; 2021:143-164. 11. Engerix-B. Package insert. GlaxoSmithKline; 2020. 12. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD.
INDICATION
HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
IMPORTANT SAFETY INFORMATION
Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.